In this study, the ABCC1 inhibitor MK571 significantly improved endothelial dysfunction and reduced atherosclerotic lesion formation in the apolipoprotein E (ApoE) knockout mouse model of atherosclerosis. Here, APOE is linked to endothelial dysfunction.